GLP-1 Success Drives Eli Lilly's Projected $47B FCF by 2030
LLY sits 80% above its 52-week low of $623.78.
Summary
Eli Lilly projects its Free Cash Flow (FCF) to nearly double to $47 billion by 2030, up from approximately $22 billion currently. This significant financial outlook is fueled by the strong performance of its GLP-1 drug pipeline, which includes positive late-stage trial results for Foundayo, Retatrutide, and Eloralintide, with global regulatory submissions planned. The company is also noted as a leader in AI-healthcare. This follows a period of strong growth for Eli Lilly, marked by recent FDA approval for Foundayo, robust Q1 2026 earnings, and strategic investments. The projected FCF growth is highly material for a company of this scale, underscoring its dominant position in the obesity and diabetes markets and future profitability.
At the time of this announcement, LLY was trading at $1,123.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,166.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.